Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.

Tumori - 1 Jan 2000

Varol Umut, Yildiz Ibrahim, Salman Tarik, Karabulut Bulent, Uslu Ruchan

Abstract excerpt

The identification of clinical, biochemical and molecular markers to predict or monitor the efficacy of bevacizumab represents a major point in the treatment of patients with metastatic colorectal cancer. Studies and genetic analyses have been conducted to identify a predictive biomarker of bevacizumab efficacy. However, genes of the angiogenic pathway and angiogenic biomarkers vary substantially, thereby causing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Drug Eruptions

Share to Endothelial Progenitor Cells

Share to Genes, ras

Share to Neovascularization, Pathologic

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 25296585
DOI: 10.1700/1636.17888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.PMID 25296585Read ↗

Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.Semantic proximity Read ↗

Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.Semantic proximity Read ↗

Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.Semantic proximity Read ↗

Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.Semantic proximity Read ↗

Biomarkers of Angiogenesis in Colorectal CancerSemantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.Semantic proximity Read ↗

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.Semantic proximity Read ↗

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.Semantic proximity Read ↗

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.